Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1903MR)

This product GTTS-WQ1903MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1903MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12330MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ3295MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ9335MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ12589MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ3468MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ4549MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ14161MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ14083MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-421
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW